Pfizer Agrees to Buy Anacor for $5.2 Billion

Pfizer agreed to buy Anacor Pharmaceuticals for $5.2 billion, gaining control of an experimental treatment for the skin condition known as eczema in its first deal since walking away from a $160 billion takeover of Allergan. Bloomberg's Cynthia Koons reports on "Bloomberg Markets." (Source: Bloomberg)

Avianca CEO Says Kingsland Suit Has No Merit
22:50 - Hernan Rincon, Avianca Holdings chief executive officer, comments on the company's negotiations with United Continental and the future of airlines in Latin America. He speaks with Bloomberg's Vonnie Quinn on "Bloomberg Markets." (Source: Bloomberg)
  • Why Junk Bonds Have a Cushion Against Rising Rates
  • Oanda Looks to Democratize FX Trading
  • Evercore's DeBusschere Says Markets Put Fed 'in a Box'